In a phase Ib/II study, APL-101 in combination with Andatinib (an EGFR-TKI) is ongoing in patients with locally advanced or metastatic NSCLC with MET overexpression or MET amplification after failure of treatment with EGFR-TKI (NCT06343064). This evidence concerns the gene EGFR and non-small cell lung carcinoma.